Non-invasive cardiac imaging evaluation of patients with chronic systolic heart failure: a report from the European Association of Cardiovascular Imaging (EACVI). by Gimelli, Alessia et al.
CURRENT OPINION
Non-invasive cardiac imaging evaluation of
patients with chronic systolic heart failure: a report
from the European Association of Cardiovascular
Imaging (EACVI)
Alessia Gimelli1, Patrizio Lancellotti2, Luigi P. Badano3, Massimo Lombardi4,
Bernhard Gerber5, Sven Plein6, Danilo Neglia1, Thor Edvardsen7,8, Anastasia Kitsiou9,
Arthur J.H.A. Scholte10, Stephen Schro¨der11, Bernard Cosyns12, Paola Gargiulo13,
Jose Luis Zamorano14, and Pasquale Perrone-Filardi15*
1Fondazione CNR/Regione Toscana G. Monasterio, Pisa, Italy; 2Department of Cardiology, University of Lie`ge Hospital, GIGA Cardiovascular Sciences, Heart Valve Clinic, University
Hospital Sart Tilman, Lie`ge, Belgium; 3Department of Cardiac, Thoracic and Vascular Sciences, University of Padua, Padua, Italy; 4Multimodality Cardiac Imaging Section, I.R.C.C.S.,
Policlinico San Donato, Milan, Italy; 5Division of Cardiology, Cliniques Universitaires St. Luc, Universite´ Catholique de Louvain, Brussels, Belgium; 6University of Leeds, Leeds, UK;
7Cardiology Department, Oslo University Hospital, Rikshospitalet and University of Oslo, Oslo, Norway; 8Center of Cardiological Innovation, Oslo, Norway; 9Cardiology Department,
Sismanoglio Hospital, Athens, Greece; 10Cardiology Department, Leiden University Medical Center, the Netherlands; 11Klinik am Eichert, Go¨ppingen, Germany; 12Cardiology
Department, CHIREC – Braine, In Vivo Molecular and Cellular Imaging Center, Brussels, Belgium; 13SDN Foundation, Institute of Diagnostic and Nuclear Development, Naples, Italy;
14Hospital Ramon y Cajal, University Alcala de Henares, Madrid, Spain; and 15Department of Advanced Biomedical Sciences, Federico II University, Naples, Italy
Received 12 December 2013; revised 17 July 2014; accepted 9 October 2014; online publish-ahead-of-print 21 November 2014
Introduction
In patients with heart failure (HF) and reduced ejection fraction (EF),
non-invasive cardiac imaging provides diagnostic, prognostic, and
therapeutic information and assists decision-making. The aim of
this consensus paper is to provide an overview of the clinical applica-
tions of non-invasive cardiac imaging in the management of HF
patients with systolic dysfunction, mostly focusing on impact on clin-
ical decision-making (Figure 1).
Diagnosis
In patients with suspected HF, an electrocardiogram, chestX-ray, and
brain natriuretic peptide (BNP or NT-proBNP) assay should be per-
formed before non-invasive cardiac imaging,1 but in particular clinical
situations with high likelihood of the disease, i.e. symptoms of HF in
patients with previous myocardial infarction, cardiac imaging might
be directly performed without previous BNP assay.
Left ventricular (LV) systolic dysfunction, conventionally identified
when EF at rest is ,50%, is detected in 50% of patients with HF.
However, EF does not accurately reflect the contractile status of
the myocardium as it is influenced by loading conditions. In addition,
EF does not reflect cardiac output that can be preserved in patients
with low EF but large left ventricle, or decreased in patients with
normalEFbut reducedLVchamber sizeor impaireddiastolic function
or severe mitral regurgitation. Additional parameters that are usually
abnormal in patients with systolic HF include increased end-diastolic
diameter and volume (LV diameter .60 mm or 32 mm/m2 with LV
volume .97 mL/m2) and end-systolic diameter and volume (LV
diameter .45 mm or 25 mm/m2 with LV volume .43 mL/m2).
To measure these parameters and establish the diagnosis of systolic
HFeither an echocardiogram orcardiac magnetic resonance (CMR) at
rest should be performed.1
Usingechocardiography, EF shouldbecalculated adopting theapical
biplane rule (modified Simpson rule), with the use of contrast agent
when ,80% of the endocardial border is visualized, whereas visual
assessment of EF is not recommended.2 However, clinicians should
be aware of the suboptimal reproducibility of echocardiographic EF
measurement3 and rely on examinations performed by experienced
operators. Although still not widely diffused, three-dimensional echo-
cardiography improves reproducibility of EF measurement.2
Left ventricular systolic function can also be assessed measuring
atrioventricular plane systolic excursion, systolic tissue Doppler
velocities, and deformation indexes, including strain and strain rate.
Although abnormalities of these indexes precede EF decrease, and
might bemoresensitive to identifypre-clinical HF,4 their use in clinical
practice is still limited due to reduced reproducibility and lack of
standardization.
Echocardiography allows accurate evaluation of LV diastolic func-
tion that is commonly impaired in patients with reduced EF.
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Guidelines recommend a comprehensive evaluation of echocardio-
graphic and Doppler parameters, to assess LV mass, left atrial dilation,
and functional diastolic indexes. These latter should include tissue
Doppler imaging-derived early diastolic myocardial velocities (e′)
(normal .8 cm/s septal, .10 cm/s lateral, or .9 cm/s average)
that reflects myocardial relaxation and the E/e′ ratio (normal ,15)
that reflects filling pressure. The mitral inflow E/A ratio (normal 1–2)
identifies the pattern of diastolic dysfunction (restrictive if .2,
impaired relaxation if ,1 or ‘pseudonormal’ if between 1 and 2
but decreasing .0.5 during the Valsalva maneuver) providing
insights into the loading conditions of the left ventricle that can assist
therapeutic management.
Cardiac magnetic resonance is the most valuable alternative to
echocardiography and represents first-line technique in patients
with unfavourable acoustic window, like those with pulmonary dis-
eases, or in patients with complex congenital diseases, or in patients
in whom characterization of myocardial tissue is needed (see below).
At variance with echocardiography, measurements are independent
on geometric assumptions, making CMR the gold standard technique
for the assessment of EF and LV volumes5 (Figure 2). In addition, the
right ventricle can be accurately evaluated and, by combining cine and
flow-sensitive CMR imaging, valvular regurgitation and intracardiac
shunt volumes can be quantified.5
However, lack of portability, reduced availability, and higher costs
are current limitations to the use of CMR. In addition, CMRcannot be
performed in claustrophobic patients or in patients with severe renal
impairment (.IV renal disease stage), in whom administration of
gadolinium is contraindicated for the risk of nephrogenic systemic fi-
brosis.6 Increased use of CMR compatible pacemakers will progres-
sively reduce the numberofpatientshostingdevicesprecludingCMR,
but implantable cardioverter defibrillator (ICD) and cardiac resyn-
chronization therapy (CRT) remain a contraindication in many
patients with HF.7
Cardiac computed tomography (CCT) allows quantification of
LVEF and volumes that can be achieved using a spiral mode with
image data acquisition throughout the entire cardiac cycle, leading
to higher radiation exposure, or acquiring both systolic and diastolic
phases with step-and-shoot protocol, with modest radiation dose in-
crease.8 However, CCT has currently limited role to assess cardiac
function in patients with suspected HF.1
Figure1 Use of cardiac imaging for the management of patients with chronic systolic heart failure. HF, heart failure; BNP, brain natriuretic peptide;
CMR, cardiac magnetic resonance; EF, ejection fraction; CAD, coronary artery disease; CCTA, cardiac computed tomographic angiography; SPECT,
single photon emission computed tomography; PET, positron emission tomography; ICD, implantable cardioverter defibrillator; CRT, cardiac resyn-
chronization therapy; OMT, optimal medical therapy. *might precede stress imaging in patients with angina.
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Assessment of LV function is also recommended in asymptomatic
patients with known or suspected coronary artery disease (CAD) in
current guidelines (Class I, levelof evidenceA)9 and in patientsunder-
going chemotherapy.10 In this latter category, chemotherapy should
not be initiated or should be suspended when EF ≤ 44% or a signifi-
cant decrease (.10 points from baseline) during the course of
therapy.
Aetiology of heart failure
Heart failure with reduced EF can be due to several pathological con-
ditions, including idiopathic dilated cardiomyopathy, valvular, hyper-
tensive and ischaemic heart disease, toxin-induced cardiomyopathies
(e.g. doxorubicin, herceptin, alcohol), as well as congenital heart
disease. Right ventricular systolic dysfunction is usually a consequence
of LV dysfunction, but can also develop as a result of right ventricular
infarction, pulmonary hypertension, chronic severe tricuspid regurgi-
tation, or arrhythmogenic right ventricular dysplasia.
Coronary artery disease accounts for two-thirds of HF due to LV
systolic dysfunction and is associated with increased mortality com-
pared with non-CAD aetiology.11 Ischaemic LV systolic dysfunction
is diagnosed in patients with a history of myocardial infarction or
angiographic evidence of CAD.11 Invasive coronary angiography
has longbeenconsidered thegoldstandard toruleoutCADinpatients
with HF.11 However, it may not be the most appropriate first-line test
in individuals with low pre-test probability of CAD. It is debated
Figure 2 Head-to-head comparison of left ventricular function assessment with 64-row computed tomography (64-row CT), biplane left cine-
ventriculography (CVG), and two- and three-dimensional transthoracic echocardiography (2D Echo; 3D Echo), using cardiac magnetic resonance
(CMR) as the reference standard. The results of Bland–Altman analysis of intermethod agreement for left ventricular ejection fraction (EF) and
volumes, conducted on 36 patients who underwent 64-CT, CVG, 2D Echo, 3D Echo, and CMR studied by Groupier et al., are shown. The mean
difference of CMR and index tests is represented by circles with their limit of agreement (95% confidence interval, +1.96 SD). Sixty-four-row
CT did not overestimate or underestimate EF (A), end-diastolic volume (EDV) (C), or end-systolic volume (ESV) (D) in comparison to CMR, but
significantly overestimated stroke volume (SV) (B). CVG significantly overestimated all left ventricular volumes (B to D), and 2D Echo and 3D
Echo showed a significant underestimation of EDV (C ) and ESV (D), whereas SV was significantly underestimated by 2D Echo (B). CVG and 3D
Echo showed significantly larger limits of agreement (P, 0.05) than 64-row CT for EF (A) and SV (B), whereas for EDV (C) and ESV (D) there
was no significant difference. For 2D Echo, limits of agreement were larger for SV, but not for EF (A) and volumes (C and D). From Greupner
et al.5+ ¼ significant (p, 0.05 overestimation vs. MRI);2 ¼ significant (p, 0.05 underestimation vs. MRI); #¼ significantly larger limits of agree-
ment vs. 64-row CT.
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whether patients with HF and intermediate to high likelihood of CAD
should undergo invasive coronary angiography following or preceding
non-invasive stress tests. As recommended in European and North-
American guidelines,1 coronary angiography should be performed in
patients with angina, whereas in other circumstances, although un-
proven in clinical studies, a strategy of stress imaging evaluation of is-
chaemia and viability followed by invasive angiography in patients
with evidence of CAD seems the most reasonable approach, since
there is no demonstrated benefit of revascularization in patients
without ischaemia or viability who might be unnecessarily exposed
to the risk of angiography (especially worsening of renal function in
patients with reduced glomerular filtration rate).6
In some patients, insights in the aetiology of HF can be obtained by
examination of the left ventricle under resting conditions (Table 1).
Regional wall motion abnormalities point to an ischaemic aetiology
of HF, whereas typical echocardiographic morphological 7patterns
are seen in LV non-compaction (Figure 3) or Takotsubo.12 Similarly,
CMR at rest, with late gadolinium enhancement (LGE), may show
characteristic aetiological patterns. In non-ischaemic dilated cardio-
myopathy, cine images typically show dilated and globally dysfunc-
tional ventricles with LGE in the midwall or subepicardial wall of
the left ventricle whereas in ischaemic HF LGE is typically observed
in the subendocardium.13 However, it has been reported that up
to 13% of patients with dilated cardiomyopathy and normal coronary
arteries show LGE typical of ischaemic LV dysfunction (Figure 4).
Cardiac magnetic resonance is also well suited to diagnose non-
compaction cardiomyopathy given its high spatial resolution and ex-
cellent tissue contrast. Other forms of HF may show characteristic
patterns on LGE CMR, including sarcoidosis, amyloidosis, Chagas
disease, and Fabry’s disease and T2* mapping can be used to diagnose
myocardial iron overload (Table 1).
In most patients with HF and systolic dysfunction, an imaging stress
test is recommended to rule out CAD and evaluate the functional
significance of coronary stenosis. The choice among different tests
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Table 1 Aetiology of heart failure: possible applications of the different imaging techniques (modified from McMurray
et al.1)
Echo CMR SPECT PET CT
CAD
Ischaemia +++ +++ ++++ ++++
Hibernation +++ +++ ++++ ++++
Necrosis ++ ++++ ++ +++
Anatomy ++++
Valvular
Stenosis ++++ + ++
Regurgitation ++++ ++
Myocarditis + +++
Sarcoidosis + +++ ++
Hypertrophic CMP
HCM ++++ ++++
Amyloidosis +++ ++++ ++ +
Dilated CMP
Myocarditis + +++
Eosinophilic syndromes + +++
Iron: haemocromatosis + +++
Iron: thalassemia + +++
Restrictive CMP
Pericarditis ++ ++ +
Amyloidosis ++ +++ ++
Endomyocardial fibrosis + +++
Anderson-Fabry + +
Unclassified CMP
Takotsubo ++ ++ ++
ARVC +++ +++
Selection of a test in daily practice should consider availability, local expertise, advantages/disadvantages, and, in the case of several questions to address, which test could best answer
several of them.
Grades: ++++, very highly valuable; +++, highly valuable; ++, valuable; +, of interest. CAD, coronary artery disease; CMP, cardiomiopathy; ARVC, arrhythmogenic right
ventricular cardiomyopathy.
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relies on several factors including patient’s characteristics (body size,
claustrophobia, presence of non-CMR compatible devices, exercise
capacity, etc.), co-morbidities (test using contrast agents should
preferably not be used in patients with renal dysfunction), as well
as logistic constraints (availability, operator experience). A frequent
particular situation is represented by patients with suspected
HF and left bundle branch block in whom the accuracy of exercise
single photon computed tomography (SPECT) to diagnose CAD
is reducedcomparedwith pharmacological SPECTorstress echocar-
diography,14 that should be preferred.
Cardiac computed tomography angiography (CCTA) can be used
for non-invasive assessment of coronary arteries, using scan proto-
cols, e.g. prospective triggering ultra-high-pitch, very large detectors,
advanced reconstruction algorithms, or the step-and-shoot mode
that substantially reduce (,2 mSv) radiation exposure.15 However,
CCTA does not assess the functional significance of coronary stenosis
that is relevant forpatients’management (seebelow).Therefore, in the
CAD rule out workup, CCTA might be considered in patients with
equivocal stress imaging results or in those with low intermediate
(15% to 50%) pre-test probability of CAD.9
Figure 3 Echocardiographic and cardiac magnetic resonance typical patterns in heart failure due to isolated ventricular non-compaction cardio-
myopathy.Theechocardiographicparasternal long-axis viewwithout (A) andwith colourDoppler (B) andapical four-chambers view(C ) showacase
of non-ischaemic dilated cardiomyopathy due to isolated ventricular non-compaction. Images show the presence of non-compacted endocardial
layer of trabecular meshwork with deep endomyocardial spaces localized on inferior (A) and lateral (C ) walls (maximal end-systolic ratio of
non-compacted to compacted layers .2) associated with evidence of deep perfused intertrabecular recesses (B). These morphological finding
are diagnostic for isolated ventricular non-compaction cardiomyopathy (Jenni criteria43). CMR (D) confirms the diagnosis.
Figure4 Example of cardiac magnetic resonance late gadolinium enhancement patterns in different aetiologies of heart failure. Ischaemic left ven-
tricular dysfunction typically presents with sub-endocardial or transmural late gadolinium enhancement. Non-ischaemic cardiomyopathy either has
no detectable LGE or shows a midseptal stripe pattern. Myocarditis typically shows a midmyocardial or epicardial enhancement in the lateral or
anterior and septal walls. Hypertrophic cardiomyopathy shows a wide range of enhancement patterns, including LGE at the septal insertion
points. In amyloidosis LGE is typically diffuse and optimal nulling of myocardial signal can be difficult due to the diffuse enhancement.
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Prognosis and management of
heart failure patients based on
imaging parameters
The main goal of cardiac imaging is to guide patients’ management, ul-
timately modifying prognosis. Yet, clinicians should recognize that
among several imaging parameters that predict outcomes in patients
with HF, only few are advocated in guidelines as gate-keepers in the
clinical decision-making.
Ejection fraction at rest remains the most powerful prognostic and
decision-making parameter in patients with systolic HF. In fact, EF,
35% at rest represents the only imaging parameter recommended in
Guidelines for device implantation (ICD, CRT).16,17
Quantification and characterization of mitral regurgitation from
echocardiographic imaging also drives therapeutic strategy in symp-
tomatic patients. The majority of patients with systolic HF show
moderate-to-severe secondary mitral regurgitation due to LV remod-
elling that substantially affect clinical status and prognosis.18 Although
there is no evidence of an impact onmortality, surgical repair is recom-
mended inpatientsundergoingbypasscardiac surgery.19Percutaneous
intervention using MitraClip improves clinical status and reduce valve
dysfunction, death, and moderate-to-severe mitral regurgitation at 12
months20,21 in HF patients, and this procedure represents an alterna-
tive to surgery in patients with very high surgical risk.19 Echocardiog-
raphy has a key role to identify symptomatic HF patients with mitral
regurgitation suitable for MitraClip treatment.22
Stress imaging provides key information for management of patients
with systolic HF. Inpatients with low flow–low gradient aortic stenosis
and reduced EF (defined by valve area ,1 cm2, EF, 40%, mean
gradient,40 mmHg), dobutamine stress echocardiography identifies
severe aortic stenosis and patients with contractile reserve who show
an acceptable operative risk (5%) and more favourable long-term
prognosis.23
In patients with ischaemic HF, the extent and severity of inducible is-
chaemia, independentlyonthe imagingmodalityused, is akeyprognostic
determinant and identifies patients at high risk in whom revasculariza-
tion is recommendedbyGuidelines.1,9 Althoughbasedonretrospective
studies, Guidelines recommend revascularization in patients with
.10% inducible ischaemia in a nuclear imaging stress study [either
SPECT or positron emission tomography (PET)] or with .3 echocar-
diographic or CMR ischaemic segments during stress examination.9 In
addition, inpatientswith ischaemicHFassessmentofmyocardial viability
has been used to recommend revascularization (in patients with evi-
dence of viability and suitable coronary anatomy) or medical therapy
(in patients with mostly necrotic myocardium and no inducible ischae-
mia).24 Yet, the STICH study25 reported no impact of viability on the
primary endpoint of all-cause mortality in patients with ischaemic
severe HF randomized to revascularization or optimal medical
therapy. This trial contradicted results of a previous meta-analysis of
retrospective studies reporting a substantial benefit of revascularization
in ischaemic HF patients with viability.24 Despite its relevance, the
STICHtrialpresentedsomelimitations26,27 andcurrentGuidelines9rec-
ommend revascularization in ischaemic patients with LV viability.10%,
although the risk-benefit of this approach remains unproven.
In order to assess viability, the recovery of regional contractile
function at rest was used as gold standard by all imaging techniques.
To this gold standard, nuclear techniques (either SPECT or PET)
show greater sensitivity but reduced specificity compared with tech-
niques that assess contractile reserve (echocardiography, CMR).
These differences can be more relevant in particular clinical scenarios
like patients with dysfunctional myocardium subtended by occluded
vessel in whom sensitivity of contractile reserve is suboptimal
compared with nuclear techniques.28
Figure5 Accuracy for predicting recovery of regional dysfunction in heart failure patients. Assessment of scar using late gadolinium enhancement
(left panel) predicts recovery of function with the same relationship reported for nuclear techniques (right panel). The extension of late gadolinium
enhancement is expressed as % and reported on x-axis in left diagram; the extension of SPECT tracers uptake is expressed as % and reported on
x-axis in right diagram. The accuracy in predicting recovery of regional dysfunction at rest, indicated as % functional recovery (% Fnx recovery), is
quite high in myocardial segments showing very limited LGE extension (lower than 26%) or very preserved SPECT tracers uptake (higher than
60%). Instead, the accuracy for predicting recovery of regional dysfunction at rest become suboptimal for regions showing intermediate extent
of LGE similarly to regions showing intermediate uptake of SPECT tracers. Modified from Kim et al.29 (left) and Perrone-Filardi et al.44 (right).
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Cardiac magnetic resonance evaluation of viability relies on the as-
sessment of transmural distribution of scar using LGE.29 However, as-
sessmentof scarusingLGEpredicts recoveryof functionwith thesame
relationship reported for SPECT,29,30 showing that accuracy is high in
myocardial segments with limited fibrosis or preserved SPECT tracers
uptake, but becomes suboptimal for regions showing intermediate
extent of fibrosis or intermediate uptake of SPECT tracers (Figure 5).
Reduced myocardial thickness was also claimed to predict myocar-
dial viability, but up to 18% of dysfunctional myocardial regions with
diastolic wall thickness ,6 mm show reduced (,50%) scar burden
and may improve function and thickness after revascularization.31
Yet, implications of myocardial viability are likely more complex
than just reflected by recovery of myocardial function at rest. In
fact, favourable functional or morphological LV changes may occur
after revascularization, without substantial changes in systolic func-
tion at rest. Yet, no effects of revascularization other than recovery
of contractile function have been adequately explored and this repre-
sents a gap in evidence deserving further investigation.
In patients with non-ischaemic systolic HF, CMR LGE predicts all-
cause mortality and hospitalization for HF, sudden cardiac death, in-
ducible ventricular arrhythmias, and appropriate ICD shocks,32 but
these prognostic information do not affect management strategies.
A relevant potential applicationofnon-invasive imaging inHF patients
is the selectionof patients fordevices (ICD, CRT). Echocardiographic
approaches to identify CRT responders looked at the assessment of
ventricular asynchrony. However, none of 12 indexes of asynchrony
tested in the PROSPECT trial resulted enough accurate for clinical
practice.33 Indeed, in HF patients with narrow QRS but echocardio-
graphic evidence of asynchrony CRT implantation did not influence
outcomes.34 Instead, the CMR approach is based on the assumption
that lead implantation is not efficacious in mostly necrotic myocardial
areas identified by LGE.35 However, this approach was never tested
in large multicentre studies and is currently not recommended for
patient selection for CRT.
Labelling of meta-iodobenzylguanine with radioactive 123iodine
(123I-MIBG) depicts the status of cardiac sympathetic innervation.36
Reduced myocardial 123I-MIBG uptake independently predicts ven-
tricular arrhythmia, sudden cardiac death, and ICD firing in HF
patients.37 Yet, 123I-MIBG has currently no indication in Guide-
lines1,17 for selection of patients candidates to ICD. It would be
worth to assess in future studies whether 123I-MIBG imaging or
other cardiac innervation imaging techniques may identify high-risk
patients with mild-to-moderate systolic dysfunction (EF . 35% to
normal) currently not candidate to ICD implantation.
Imaging follow-up of heart failure
patients
Heart failure patients should be monitored with the goal of identi-
fying sub-clinical haemodynamic deterioration to reduce re-
hospitalizations and improve survival. There is no current evidence
supporting periodic evaluation of LV function in HF patients who
remain stable. However, improvement of EF and reduction of LV sys-
tolic and diastolic volumes due to therapy are the only imaging para-
meters predicting improved prognosis in HF patients.38 Similarly,
reduction of LV volumes of at least 10–15% from pre-implantation
values is used to define responders to CRT and predicts improved
outcomes.39 Thus, a reasonable approach would be to re-assess LV
function in patients reporting functional deterioration or undergoing
CRT implantation. In addition, LV function should be re-assessed
periodically in patients undergoing chemotherapy (i.e. after adminis-
trationofhalf the total anthracycline cumulativedoseandbeforeeach
subsequent dose).40
Perspective: multi-modality
imaging in heart failure
Multi-modality imaging represents the combination of anatomical,
morphological, and functional parameters from non-invasive imaging
techniques. Complementary imaging modalities may be performed
separately or in a single-step approach using hybrid systems. Hybrid
SPECT-CT or PET-CT enable anatomic and functional evaluation of
coronary stenosis41 whereas hybrid PET/CMR was recently intro-
duced to integrate metabolic, perfusion, structural, and functional
parameters.42
Although the possibility to obtain complementary information in a
single test is appealing, the clinical value and the cost–benefit of these
approaches in HF patients remain undetermined and their use must
be considered investigational.
Conclusions
Successful application of imaging techniques in HF patients results
from integration into clinical care and requires adequate training of
cardiovascular specialists. Appropriate utilization of imaging remains
the shared responsibility of clinicians who use imaging to assist clinical
decision-making and of physicians who perform imaging procedures
knowing their strengths and limitations.
Conflict of interest: none declared.
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